重组人促红细胞生成素治疗食管癌癌性贫血的临床观察  

Clinical observation of recombinant human erythropoietin(rhEPO) on the management esophageal cancer-related anemia

作　　者：牛顺海 陶海云[2] 樊青霞[2] 廖益辉 

机构地区：[1]河南省滑县人民医院肿瘤科 [2]郑州大学第一附属医院肿瘤科 [3]广东省新兴县人民医院口腔科

出　　处：《中国当代医药》2014年第1期76-78,共3页China Modern Medicine

基　　金：广东省云浮市医药卫生科研立项课题(2011B062)

摘　　要：目的观察重组人促红细胞生成素（rhEPO）治疗食管癌癌性贫血的最佳时间。方法67例轻度贫血食管癌患者，化疗前基础血红蛋白（Hb）为100～120g／L。将其随机分为两组，早使用组31例患者在入组与化疗时同时使用rhEPO，晚使用组36例患者在Hb降低至〈90g／L时使用rhEPO。rhEPO剂量为150U／kg，3次／周，皮下注射。治疗期间发生铁缺乏、疗效不明显的患者加用琥珀酸亚铁0．1g口服，3次／d。结果早使用组和晚使用组患者Hb基础水平分别为（110．0±0．7）g/L和（112．0±0．9）g/L。早使用组患者的Hb及血细胞比容（HCT）显著增加（P〈0．05）。晚使用组患者的Hb和HCT值有所下降（P〈0．05），用药5～8周时与化疗前相比差异有统计学意义（P〈0．05）。结论早使用重组人促红细胞生成索能显著提高患者的Hb水平,改善食管痛痛忡贫向患者的牛活质量．Objective To evaluate the best time of the recombinant human erythropoietin （rhEPO） for anemic esophageal cancer patients receiving chemotherapy. Methods 67 cases of mild anemia in patients with esophageal cancer whose basic hemoglobin level between 100-120 g/L before chemotherapy were enrolled into this study and were randomly divided into two groups,the early use group of 31 patients with chemotherapy at the same time used rhEPO,the night use group 36 patients were used rhEPO in Hb reducing to less than 90 g/L.Patients received rhEPO at a dose of 150 UPKg subcutaneously TIW.Patieuts with iron deficiency and curative effect insufficient took ferrous succinate 0.1 g orally, three times a day. Results The Hb basic level of the early use group and night use group respectively was （110.0_＋0.7） g/L and （112.0＋0.9） g/L.The level of Hb and HCT increased significantly in early use group （P〈0.05）,t The level of Hb and HCT declined significantly in early use group （P〈0.05）.There was a significant defference between drug used in 5 to 8 weeks and before chemotherapy （P〈0.05）. Conclusion Early use of rhEPO increases Hb and improves the quality of anemic patients with esophageal cancer.

关 键 词：癌性贫血 重组人促红细胞生成素 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]